MetaCap

Anixa Biosciences (ANIX) vs Retension Pharmaceuticals (RTSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $84.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-15.86%RTSN-0.19%
+59%+20%-19%
Oct 9, 20261 yearNov 20, 2026
ANIX-15.86%RTSN-0.19%
+48%+14%-19%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus RTSN key metrics
MetricANIXRTSN
Share price$2.44$10.51
Market cap$84.82M$87.57M
1-day change-6.15%-19.22%
YTD return-21.79%—
1-year return-43.78%—
5-year return-38.69%—
EPS (TTM)$-0.32$-2.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-10.93M—
52-week high$5.46$18.64
52-week low$2.32$9.23
Distance from 52-week high-55.31%-43.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+296.31%+391.63%
Average volume282.29K144.93K
Shares outstanding34.76M8.33M
Employees412
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ANIX vs RTSN FAQ

Which is bigger, Anixa Biosciences or Retension Pharmaceuticals?

Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $84.82M for Anixa Biosciences (ANIX).

Are Anixa Biosciences and Retension Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons